<code id='BE4BAEAF96'></code><style id='BE4BAEAF96'></style>
    • <acronym id='BE4BAEAF96'></acronym>
      <center id='BE4BAEAF96'><center id='BE4BAEAF96'><tfoot id='BE4BAEAF96'></tfoot></center><abbr id='BE4BAEAF96'><dir id='BE4BAEAF96'><tfoot id='BE4BAEAF96'></tfoot><noframes id='BE4BAEAF96'>

    • <optgroup id='BE4BAEAF96'><strike id='BE4BAEAF96'><sup id='BE4BAEAF96'></sup></strike><code id='BE4BAEAF96'></code></optgroup>
        1. <b id='BE4BAEAF96'><label id='BE4BAEAF96'><select id='BE4BAEAF96'><dt id='BE4BAEAF96'><span id='BE4BAEAF96'></span></dt></select></label></b><u id='BE4BAEAF96'></u>
          <i id='BE4BAEAF96'><strike id='BE4BAEAF96'><tt id='BE4BAEAF96'><pre id='BE4BAEAF96'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:focus    Page View:26352
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In